6F3V | pdb_00006f3v

Backbone structure of bradykinin (BK) peptide bound to human Bradykinin 2 Receptor (B2R) determined by MAS SSNMR

External Resource: Annotation

Gene Ontology: Gene Product Annotation
InterPro: Protein Family Classification
Pharos: Disease Associations

Gene Ontology: Gene Product Annotation Gene Ontology Database Homepage

Chains	Polymer	Molecular Function	Biological Process	Cellular Component
A	Bradykinin (BK)	protein binding binding signaling receptor binding enzyme regulator activity molecular function inhibitor activity peptidase regulator activity molecular function regulator activity enzyme inhibitor activity cysteine-type endopeptidase inhibitor activity peptidase inhibitor activity endopeptidase regulator activity endopeptidase inhibitor activity hormone activity molecular function activator activity protein binding binding signaling receptor binding enzyme regulator activity molecular function inhibitor activity peptidase regulator activity molecular function regulator activity enzyme inhibitor activity cysteine-type endopeptidase inhibitor activity peptidase inhibitor activity endopeptidase regulator activity endopeptidase inhibitor activity hormone activity molecular function activator activity signaling receptor regulator activity receptor ligand activity signaling receptor activator activity cation binding transition metal ion binding zinc ion binding ion binding metal ion binding small molecule binding heparin binding glycosaminoglycan binding carbohydrate derivative binding sulfur compound binding	multicellular organismal process regulation of body fluid levels wound healing response to stimulus hemostasis biological regulation blood coagulation response to stress coagulation regulation of biological quality response to wounding positive regulation of cytosolic calcium ion concentration regulation of biological process positive regulation of programmed cell death multicellular organismal process regulation of body fluid levels wound healing response to stimulus hemostasis biological regulation blood coagulation response to stress coagulation regulation of biological quality response to wounding positive regulation of cytosolic calcium ion concentration regulation of biological process positive regulation of programmed cell death regulation of cellular process regulation of apoptotic process positive regulation of biological process regulation of programmed cell death cell death positive regulation of apoptotic process cellular process apoptotic process programmed cell death positive regulation of cellular process regulation of response to external stimulus negative regulation of biological process regulation of response to wounding regulation of coagulation regulation of response to stress regulation of multicellular organismal process regulation of hemostasis negative regulation of response to stimulus negative regulation of wound healing regulation of blood coagulation negative regulation of blood coagulation response to external stimulus negative regulation of response to wounding negative regulation of hemostasis negative regulation of coagulation regulation of response to stimulus negative regulation of response to external stimulus regulation of wound healing negative regulation of multicellular organismal process negative regulation of proteolysis regulation of protein metabolic process negative regulation of metabolic process primary metabolic process regulation of macromolecule metabolic process regulation of primary metabolic process regulation of proteolysis proteolysis negative regulation of cellular process metabolic process protein metabolic process macromolecule metabolic process regulation of metabolic process negative regulation of protein metabolic process negative regulation of macromolecule metabolic process regulation of tube diameter system process regulation of tube size circulatory system process vascular process in circulatory system blood vessel diameter maintenance vasodilation blood circulation regulation of anatomical structure size defense response inflammatory response cell adhesion regulation of cell adhesion negative regulation of cell adhesion	extracellular exosome membrane-bounded organelle extracellular vesicle cellular anatomical structure extracellular organelle extracellular region organelle extracellular space vesicle extracellular membrane-bounded organelle cell periphery plasma membrane membrane blood microparticle extracellular exosome membrane-bounded organelle extracellular vesicle cellular anatomical structure extracellular organelle extracellular region organelle extracellular space vesicle extracellular membrane-bounded organelle cell periphery plasma membrane membrane blood microparticle intracellular anatomical structure membrane-enclosed lumen intracellular membrane-bounded organelle endomembrane system intracellular organelle lumen endoplasmic reticulum lumen intracellular organelle organelle lumen endoplasmic reticulum cytoplasm vesicle lumen intracellular vesicle cytoplasmic vesicle lumen secretory granule lumen cytoplasmic vesicle secretory granule secretory vesicle platelet alpha granule platelet alpha granule lumen

InterPro: Protein Family Classification InterPro Database Homepage

Chains	Accession	Name	Type
A	IPR027358	Kininogen-type cystatin domain	Domain
A	IPR000010	Cystatin domain	Domain
A	IPR046350	Cystatin superfamily	Homologous Superfamily
A	IPR002395	HMW kininogen	Family
A	IPR050735	Kininogen/Fetuin/Histidine-rich Glycoprotein	Family
A	IPR018073	Proteinase inhibitor I25, cystatin, conserved site	Conserved Site

Pharos: Disease Associations Pharos Homepage Annotation

Chains	Drug Target	Associated Disease
A	Pharos: P01042	hereditary angioedema congenital high-molecular-weight kininogen deficiency hypertensive disorder Drug Eruptions allergic disease acquired angioedema hypotensive disorder anaphylaxis C1 inhibitor deficiency occupational dermatitis drug-induced liver injury pancreatic ductal adenocarcinoma acute kidney failure mammary neoplasms, animal psoriasis hereditary angioedema congenital high-molecular-weight kininogen deficiency hypertensive disorder Drug Eruptions allergic disease acquired angioedema hypotensive disorder anaphylaxis C1 inhibitor deficiency occupational dermatitis drug-induced liver injury pancreatic ductal adenocarcinoma acute kidney failure mammary neoplasms, animal psoriasis angioedema coronary artery disease nephrosclerosis thrombotic disease

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.